Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 666 participants.
Also called NCT04968184
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 666 participants
- Sponsor
- Registry
-
NCT04968184 -
2021-003636-88
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Bosnia & Herzegovina, Bulgaria, Canada, China, Croatia, Czechia, Georgia, Germany, Hong Kong SAR China, Hungary, Israel, Latvia, Lithuania, Malaysia, Poland, Serbia, South Africa, South Korea, Spain, Taiwan
- Registry status
- Terminated
Technical summary
Registry record NCT04968184. Randomized; quadruple masking; primary purpose treatment. Start 2021-11-05 (actual); primary completion 2024-01-30 (actual). Results posted on 2026-11-04.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)
- Acronym
- Clarion-CKD
- Condition
- Chronic Kidney Diseases
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- KBP-5074
- Lead sponsor
- Novo Nordisk A/S
- Collaborator
- KBP Biosciences
Record details
- Record id
cardio:ct-nct04968184- Content hash
fb589957dfc67f37e2075915b49152790a38745d99d847f9a15bcb1d8f1a1e8e